"A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER"
2020-07-04
عنوان الدراسة
"A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER"
داعم الدراسة
Roche
دواء الدراسة
ATEZOLIZUMAB / PACLITAXEL
رقم بروتوكول الدراسة
MO39196
حالة الدراسة
Ongoing
موقع الدراسة
International Medical Center (Jeddah), King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.